Bromelain protease, bromelain, jacalin-like lectin, extract from the stem and/or the fruit of a pineapple plant, combination preparation, bromelain protease inhibitor, protein/protease mix, and glycated bromelain protein formed by exogenous non-enzymatic glycation, for use in the treatment or prophylaxis of virus infections caused by coronaviruses in a human or animal

A method of treating a human or animal infected by a coronavirus, or providing prophylaxis against a coronavirus infection, wherein the coronavirus is selected from the group consisting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and synonymous or non-synonymous mutants thereof and variants thereof and those selected from the group consisting of B.1.1.7, B.1.351, B.1.617, P.1, B.1.525, P.2, B.1.427, B.1.429, L452R, Fin-796H, B.1.526, S:H66D, S:G142V, S:D215G, S:V483A, S:D614G, S:H655Y, S:G669S, S:Q949R, S:N1187D, ORF6:K23−, ORF6:V24−, ORF6:S25−, ORF6:I26−, ORF6:W27−, ORF6:N28−, ORF6:L29−, ORF6:D30−, ORF6:Y31−, S:Y144−, E484K, VOC 20I/484Q, B.1, R.1, A.2.5, C.36, B.1.1.318, B.1.621, and B.1.623, the method comprising administering to the human or animal an effective amount of a combination preparation containing at least one bromelain protease and at least one jacalin-related lectin, wherein

• the at least one bromelain protease is selected from the group consisting of stem bromelain (SBM) (EC 3.4.22.32), fruit bromelain (EC 3.4.22.33), and ananain (EC 3.4.22.31), and
• wherein the jacalin-related lectin is pineapple lectin or jacalin-related lectin from Ananas comosus (AcmJRL), and
• wherein the weight ratio of the totality of the bromelain protease to the totality of the jacalin-related lectin is 50:50 to 0.1:99.9.